Edelweiss is bullish on Apollo Hospitals recommended Buy rating on the stock with a target price of Rs 1700 in its research report dated May 31, 2018.
Edelweiss' research report on Apollo Hospitals
Despite a strong Q4FY18 performance, the Apollo Hospitals’ (APHS) stock came off 3.8% today, after slipping 20% in past three months. What’s driving this weakness in the stock price? Regulatory headwinds have been unsettling for the hospital players. Other external factors like: i) demonetisation; ii) GST; iii) stents, knee implants and drug price control; and iv) increase in minimum wages for nurses in some states also marred sector profitability. Going ahead, some states are also trying to cap gross margins on consumables, which could further affect gross profits. Instead of addressing structural issues of the healthcare sector, populist measures are being offered. This has led to uncertainty and the APHS stock bears testimony to same.
As for APHS’ performance, having completed its capex cycle it is set to double EBITDA and reduce capex to one-third over the next three years. Maintain ‘BUY’ with SoTP-based target price of INR1,700.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.